[go: up one dir, main page]

WO2019067955A1 - Compositions et méthodes de régulation de cibles de micro-arn let-7 - Google Patents

Compositions et méthodes de régulation de cibles de micro-arn let-7 Download PDF

Info

Publication number
WO2019067955A1
WO2019067955A1 PCT/US2018/053511 US2018053511W WO2019067955A1 WO 2019067955 A1 WO2019067955 A1 WO 2019067955A1 US 2018053511 W US2018053511 W US 2018053511W WO 2019067955 A1 WO2019067955 A1 WO 2019067955A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
compound
acid
pharmaceutically acceptable
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/053511
Other languages
English (en)
Inventor
Martina Roos
William E. Lowry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2019067955A1 publication Critical patent/WO2019067955A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present disclosure provides compounds that offer a novel targeted therapeutic approach for AML.
  • the present disclosure provides methods of treating disease associated with cancer and cell-cycle regulation.
  • Compounds 44, 61, and 62 disclosed herein show robust upregulation of let-7 micro RNAs (miRNA) levels in various, cytogenetically different AML cell lines.
  • the small non-coding let-7 micro RNA family is suggested to play a key role as tumor suppressor by targeting a wide variety of oncogenes such as HMGA2, cMYC and KRAS.
  • Compound 44 offers high clinical and therapeutic significance by restoring normal levels of the endogenous tumor suppressor miRNA let-7 ultimately leading differentiation of leukemic blast cells, inhibition of LSC growth and disease progression.
  • FIGs 1A-1E show the design of screen to identify regulators of let-7 activity.
  • FIG. 1A Schematic of the let-7 Luciferase Screen. Human liver cancer cell line (HUH) is transfected each with the let-7-Luciferase and PsiCheck2-control reporter plasmids. Each transfected line is plated on its own 384 plate and both pinned with its respective compound set. The treated cells are incubated at 37C for 48 hours. ViviRen reads out the Renilla luciferase and Cell Titer Glo is a readout of cell health.
  • FIG. IB Schematic of the let- 7 Luciferase Assay.
  • FIG. 1C Transfection of let-7 mimics silences a variety of let-7 target genes as measured by RT-PCR.
  • FIG. ID Example of the fidelity of the let-7 reporter construct.
  • FIG. IE Cells transfected with the let-7 mimic showed a reduction in the readings of renilla, but the constitutive firefly luciferase was stable.
  • FIGs. 2A-2E show a secondary screen to identify compounds that suppress let-7 targets.
  • FIG. 2A a secondary screen using both constitutive and let-7 sensitive reporter to identify high confidence hits.
  • FIG. 2B tertiary screening of compounds for effect on expression of HMGA2, an established let-7 target gene by RT-PCR.
  • FIG. 2C RT-PCR for additional let-7 target genes after treatment with compounds that came out of tertiary screen.
  • FIG. 2D RT-PCR for small RNAs to determine whether any compounds regulate let-7 levels.
  • FIGs. 3A-3D show the identification of a compound that reliably suppresses expression of HMGA2.
  • FIG. 3A A dose curve of treatment with 44, as measured by the expression level of HMGA2-long.
  • FIG. 3B Treating Huh7 cells with 44 at luM for various times showed specific activity at just 8 hours.
  • FIG. 3C Treatment with 44 for two days showed specific suppression of HMGA2-long (PULSE), whereas two days after removal of these compounds, levels of HMGA2 returned to baseline (CHASE), indicating the effect of the compound is reversible.
  • FIG. 4 61 and 62 show similar effect on expression of let-7 targets such as HMGA2, NMYC and LIN28B.
  • FIGs. 5A-5D show that 44, 61 and 62 are PDE inhibitors that activate CREB.
  • FIG. 5A Huh cells were treated with 44 or 61 for 48 hours and then immunostained with an antibody that recognizes the phosphorylated version of CREB, which is typically translocated to the nucleus when active. Quantification shown on the right.
  • FIG. 5B RNA-sequencing of Huh cells treated with 44 in triplicate showed strong induction of CREB target genes (FOSB, FOS, CREB5, and ATF3).
  • FIG. 5C Dose response of 44, 61, and 62 for an effect on let-7 target gene, HMGA2.
  • FIG. 5A Huh cells were treated with 44 or 61 for 48 hours and then immunostained with an antibody that recognizes the phosphorylated version of CREB, which is typically translocated to the nucleus when active. Quantification shown on the right.
  • FIG. 5B RNA-sequencing of Huh cells treated with 44 in
  • RT-PCR for direct CREB targets FOSB and CFOS shows that 44, 61, and 62 all stimulate CREB target gene expression.
  • FIGs. 6A-6C show that extended treatment of cancer cells with let-7 inducing compounds blocks their growth.
  • FIG. 6A Equal numbers of Huh were plated across replicate wells and treated with the indicated compounds. Each day, several wells of each treatment condition were counted. Low dose of 44 slowed the growth of this cancer cell line.
  • FIG. 6B Treatment of Huh and three human squamous cell carcinoma cell lines (TSU, 22B, and 686) also showed a strong effect of 44 on cell growth at 5 days of treatment.
  • FIGs. 7A-7E show that 44 induces apoptosis and AML cell differentiation via inhibition of PI3K signaling and unfolded protein response pathway.
  • FIG. 7A shows fold changes of direct let-7 target genes ⁇ HMGAl, IL6, MYC) of genes involved in the PI3K and unfolded protein response pathway in Kasumi-1 AML cells treated with 5 ⁇ 44 and compared to control.
  • FIG. 7A shows fold changes of direct let-7 target genes ⁇ HMGAl, IL6, MYC
  • FIG. 7C shows fold changes of let- 7a- 1, -b and f-1 of Kasumi-1 cells transduced with s C/EBP , s C/ ⁇ or s CHOP, normalized to s Control and selected with puromycin for 3 days. Statistics: two-way Anova.
  • FIG. 7D shows flow Cytometry showing % of CD34 + CD38 " cells (left) and mean percentage numbers of CD34 + CD38 " Kasumi-1 cells 16h post treatment with 5 ⁇ 44 or control.
  • FIG. 7E shows cytotoxicity assessment via relative ATP production 12h post treatment with controls, clinically approved demethylating agent 5- Azacitidine (5-Aza, 5 ⁇ ) or 44 (5 - 1 ⁇ ). * P ⁇ 0.05, ** P ⁇ 0.01, *** P ⁇ 0.001, **** P ⁇ 0.0001.
  • FIGs. 8A-8C show that 44 prolongs survival in AML Xenograft models and decreases tumor burden.
  • FIG. 8B shows bioluminescence imaging (BLI) of NSG mice subcutaneously transplanted with Kasumi-1 - Luciferase expressing
  • FIGs. 9A-9C show that 44 inhibits leukemic stem cell proliferation in vivo.
  • FIG. 9A Schematic representation of NSG mice transplanted with AML patient cells treated with 10 ⁇ 44 or control for 16 h.
  • FIG. 9B Flow cytometry of hCD45+ cells (human AML) and
  • FIG. 9C % human AML engraftment (top, overall engraftment) and % LSCs of overall engraftment (bottom, LSC engraftment) in NSG bone marrow 12 weeks post transplantation of primary AML patient cells treated with 10 ⁇ 44 or control.
  • the Let-7 micro RNA family exerts its tumor suppressor and antiproliferative activities by repressing several oncogenes and by regulating key regulators of the cell cycle, cell differentiation, and apoptotic pathways (Bussing I, et al. Trends Mol Med. 2008;14(9):400-9; Johnson SM, et al. Cell. 2005;120(5):635-47).
  • Downregulation of Let-7 is a common phenomenon in several cancers including acute myeloid leukemia (AML), and restoration of normal Let-7 expression has been found to prevent cancer growth (Viswanathan SR, et al. Nat Genet. 2009;41(7):843-8). Cancer cells have been shown to exhibit reduced malignancy and motility when LIN28 is suppressed and let-7 activity is elevated (Viswanathan SR, et al. Nat Genet. 2009;41(7):843-8).
  • C/EBPs CCAAT/enhancer binding proteins
  • bYP basic region leucine zipper
  • C/EBPa, C/ ⁇ and C/ ⁇ are predominantly expressed in granulocytes, monocytes and eosinophils while C/ ⁇ is found at later stages of differentiation of granulocytes and T cells 5"7 .
  • C/EBPs are key mediators of normal myeloid differentiation as they proper control of cell cycle progression, metabolism and differentiation.
  • C/EBP expression is suppressed as a result of common leukemia- associated genetic and epigenetic alterations, such as oncogenic fusion proteins RUNXl-ETO 8 , FLT3-ITD 9 or CEBPA promoter methylation 10 .
  • Alterations in the CEBPa, - ⁇ , - ⁇ gene or in pathways that down-modulate C/EBP expression at the transcriptional, translational, or post- translational levels likely contribute to myeloid transformation by inhibiting myeloid
  • MicroRNAs are 19-22 nucleotide (nt) short non-coding RNAs that hybridize to complementary mRNA targets and either lead to their decay, cleavage or transcriptional inhibition 11"13 .
  • Aberrant miRNA expression has been shown to play an active role in malignant transformation including leukemia 14-16
  • the tumor suppressor miRNA let-7 family comprising 12 members expressed from 9 different loci (on chromosomes 3, 9, 12, 19, 21, 22 and X), represses several oncogenes including RAS, MYC, LIN28B and IL6 19 as well as cell cycle regulators such as CyclinD and E2F 20
  • let-7 family members can be inhibited by oncogenic transcription factor MYC in lymphoma and hepatocellular carcinoma 21 ' 22 and jumonji AT-rich interactive domain IB (J ARID IB) proteins in breast tumor tissue .
  • J ARID IB jumonji AT-rich interactive domain IB
  • C/EBPa binds to the promoter of the let- 7a 1, -fl and -d cluster located on chromosome 9, and consequently promotes let-7 miRNA expression 24 .
  • chromatin immunoprecipitation showed let-7f promoter as a direct target of C/ ⁇ 25 .
  • LIN28A and its homologue LIN28B as key regulators of let-7 biogenesis 26-30 through direct binding to either pre-let-7 and/or pri-let-7, thereby impairing their processing into mature, functional miRNAs.
  • LIN28A/B is upregulated in over 15% of human cancers 31 and cancer stem cells 32-36 and is associated with poor clinical outcome 34 ⁇ 37"40 5 AML included 41 . Moreover, LIN28 42-44 overexpression and let-7 45-47 loss have been associated with resistance of cancer stem cells to radiation treatment and chemotherapy.
  • Let-7 is a molecular marker and a potential therapeutic in cancer therapy such as AML.
  • the present disclosure identifies three compounds that upregulate the endogenous expression of tumor suppressor micro RNAs Let-7, efficiently suppress Let-7 target genes involved in cancer pathogenesis such as HMGA2, cMYC and Lin28b ( Figures 3B-3E, 4C), show strong growth inhibitory effects ( Figures 6A-6C), and abolish colony forming capacity in multiple cancer cell types including Leukemic stem cells in a variety of cytogenetically different AML cell Lines.
  • these compounds upregulate let-7 microRNA levels and induce apoptosis of AML cells through inhibition of UPR and PI3K pathway.
  • 44 inhibits AML tumor growth in AML Xenografts, significantly prolongs animals' survival and inhibits human leukemic stem cell proliferation in vivo.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I:
  • composition further comprises a pharmaceutically acceptable excipient.
  • R 1 is phenyl substituted with 1, 2, 3, or 4 lower alkoxy groups, such as methoxy or ethoxy. In certain embodiments, R 1 is phenyl substituted at the 2- and 4- positions with lower alkoxy groups, such as methoxy or ethoxy. In certain embodiments, R 1 is phenyl substituted at the 2-position with a lower alkoxy group, such as methoxy or ethoxy. In certain embodiments, the compound is selected from the following compounds:
  • the present invention relates to a method of increasing let-7 micro RNA levels in a patient, comprising administering an effective amount a compound of formula I:
  • R is substituted or unsubstituted phenyl
  • R 1 is phenyl substituted with 1, 2, 3, or 4 lower alkoxy groups, such as methoxy or ethoxy.
  • Rl is phenyl substituted at the 2- and 4- positions with lower alkoxy groups, such as methoxy or ethoxy.
  • Rl is phenyl substituted at the 2-position with a lower alkoxy group, such as methoxy or ethoxy.
  • the compound is selected from the following compounds:
  • the patient has a cancer.
  • the cancer is acute myeloid leukemia, colon cancer, breast cancer, prostate cancer, lung cancer, skin cancer, liver cancer, pancreatic cancer, ovarian cancer, bladder cancer, kidney cancer, esophageal cancer, cervical cancer, endometrial cancer, melanoma, brain cancer, glioma, neuroblastoma, osteosarcoma, chondrosarcoma, gastric carcinoma, glioma, mesothelioma, Kaposi sarcoma, liposarcoma, synovial sarcoma, or Wilm's tumor.
  • the cancer is liver cancer, skin cancer, such as squamous cell carcinoma, lung cancer, or acute myeloid leukemia.
  • compositions and methods of the present invention may be utilized to treat an individual in need thereof.
  • the individual is a mammal such as a human, or a non-human mammal.
  • the composition or the compound is preferably administered as a pharmaceutical composition comprising, for example, a compound of the invention and a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters.
  • aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters.
  • the aqueous solution is pyrogen-free, or substantially pyrogen-free.
  • the excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs.
  • the pharmaceutical composition can be in dosage unit form such as tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophile for reconstitution, powder, solution, syrup, suppository, injection or the like.
  • the composition can also be present in a transdermal delivery system, e.g., a skin patch.
  • the composition can also be present in a solution suitable for topical administration, such as a lotion, cream, or ointment.
  • a pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a compound such as a compound of the invention.
  • physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients.
  • carbohydrates such as glucose, sucrose or dextrans
  • antioxidants such as ascorbic acid or glutathione
  • chelating agents such ascorbic acid or glutathione
  • low molecular weight proteins or other stabilizers or excipients include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients.
  • the choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent depends, for example, on the route of administration of the composition.
  • the pharmaceutical composition also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a compound of the invention.
  • Liposomes for example, which comprise phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • phrases "pharmaceutically acceptable carrier” as used herein means a
  • composition or vehicle such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material.
  • a liquid or solid filler such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
  • a pharmaceutical composition can be administered to a subject by any of a number of routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue);
  • routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue);
  • the compound may also be formulated for inhalation.
  • a compound may be simply dissolved or suspended in sterile water. Details of appropriate routes of administration and compositions suitable for same can be found in, for example, U.S. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, as well as in patents cited therein.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
  • the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
  • Methods of preparing these formulations or compositions include the step of bringing into association an active compound, such as a compound of the invention, with the carrier and, optionally, one or more accessory ingredients.
  • an active compound such as a compound of the invention
  • the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • Formulations of the invention suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water- in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
  • capsules including sprinkle capsules and gelatin capsules
  • cachets pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth)
  • lyophile powders,
  • compositions or compounds may also be administered as a bolus, electuary or paste.
  • the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents,
  • pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets, and other solid dosage forms of the pharmaceutical compositions may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
  • compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • embedding compositions that can be used include polymeric substances and waxes.
  • the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
  • Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, cyclodextrins and derivatives thereof, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art, such
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to an active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
  • dosage forms can be made by dissolving or dispersing the active compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intraocular (such as intravitreal), intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
  • intravenous, intraocular such as intravitreal
  • intramuscular intraarterial
  • intrathecal intracapsular
  • intraorbital intracardiac
  • intradermal intraperitoneal
  • transtracheal subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
  • compositions suitable for parenteral administration comprise one or more active compounds in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
  • the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
  • Injectable depot forms are made by forming microencapsulated matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
  • active compounds can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
  • Methods of introduction may also be provided by rechargeable or biodegradable devices.
  • Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinaceous biopharmaceuticals.
  • a variety of biocompatible polymers including hydrogels, including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a compound at a particular target site.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound or combination of compounds employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound(s) being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound(s) employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the pharmaceutical composition or compound at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • therapeutically effective amount is meant the concentration of a compound that is sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of the compound will vary according to the weight, sex, age, and medical history of the subject. Other factors which influence the effective amount may include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the compound, and, if desired, another type of therapeutic agent being administered with the compound of the invention.
  • a larger total dose can be delivered by multiple administrations of the agent.
  • Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison's Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).
  • a suitable daily dose of an active compound used in the compositions and methods of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
  • the effective daily dose of the active compound may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
  • the active compound may be administered two or three times daily. In preferred embodiments, the active compound will be administered once daily.
  • the patient receiving this treatment is any animal in need, including primates, in particular humans; and other mammals such as equines, cattle, swine, sheep, cats, and dogs; poultry; and pets in general.
  • compounds of the invention may be used alone or conjointly administered with another type of therapeutic agent.
  • contemplated salts of the invention include, but are not limited to, alkyl, dialkyl, trialkyl or tetra-alkyl ammonium salts.
  • contemplated salts of the invention include, but are not limited to, L-arginine, benenthamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol,
  • contemplated salts of the invention include, but are not limited to, Na, Ca, K, Mg, Zn or other metal salts.
  • contemplated salts of the invention include, but are not limited to, 1 -hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, 1-ascorbic acid, 1-aspartic acid, benzenesulfonic acid, benzoic acid, (+)-camphoric acid, (+)- camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gent
  • the pharmaceutically acceptable acid addition salts can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, and the like. Mixtures of such solvates can also be prepared.
  • the source of such solvate can be from the solvent of
  • wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • antioxidants examples include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium
  • antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like
  • metal- chelating agents such as citric acid
  • EDTA ethylenediamine tetraacetic acid
  • sorbitol sorbitol
  • tartaric acid tartaric acid
  • phosphoric acid and the like.
  • agent is used herein to denote a chemical compound (such as an organic or inorganic compound, a mixture of chemical compounds), a biological macromolecule (such as a nucleic acid, an antibody, including parts thereof as well as humanized, chimeric and human antibodies and monoclonal antibodies, a protein or portion thereof, e.g., a peptide, a lipid, a carbohydrate), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues.
  • Agents include, for example, agents whose structure is known, and those whose structure is not known.
  • a “patient,” “subject,” or “individual” are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (including bovines, porcines, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).
  • Treating refers to taking steps to obtain beneficial or desired results, including clinical results.
  • treatment is an approach for obtaining beneficial or desired results, including clinical results.
  • Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
  • Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
  • preventing is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition.
  • a condition such as a local recurrence (e.g., pain)
  • a disease such as cancer
  • a syndrome complex such as heart failure or any other medical condition
  • prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount.
  • administering or "administration of a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art.
  • a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct).
  • a compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent.
  • Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
  • a compound or an agent is administered orally, e.g., to a subject by ingestion.
  • the orally administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.
  • the phrase "conjoint administration” refers to any form of administration of two or more different therapeutic agents such that the second agent is administered while the previously administered therapeutic agent is still effective in the body (e.g., the two agents are simultaneously effective in the patient, which may include synergistic effects of the two agents).
  • the different therapeutic compounds can be administered either in the same formulation or in separate formulations, either concomitantly or sequentially.
  • an individual who receives such treatment can benefit from a combined effect of different therapeutic agents.
  • a “therapeutically effective amount” or a “therapeutically effective dose” of a drug or agent is an amount of a drug or an agent that, when administered to a subject will have the intended therapeutic effect. The full therapeutic effect does not necessarily occur by
  • a therapeutically effective amount may be administered in one or more administrations.
  • the precise effective amount needed for a subject will depend upon, for example, the subject's size, health and age, and the nature and extent of the condition being treated, such as cancer or MDS. The skilled worker can readily determine the effective amount for a given situation by routine experimentation.
  • acyl is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.
  • acylamino is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(0)NH-.
  • acyloxy is art-recognized and refers to a group represented by the general formula hydrocarbylC(0)0-, preferably alkylC(0)0-.
  • alkoxy refers to an alkyl group having an oxygen attached thereto.
  • alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.
  • alkoxyalkyl refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O-alkyl.
  • alkyl refers to saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups.
  • a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., Ci-30 for straight chains, C3-30 for branched chains), and more preferably 20 or fewer.
  • alkyl as used throughout the specification, examples, and claims is intended to include both unsubstituted and substituted alkyl groups, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, including haloalkyl groups such as trifluoromethyl and 2,2,2- trifluoroethyl, etc.
  • C x - y or "C x -C y ", when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain.
  • Coalkyl indicates a hydrogen where the group is in a terminal position, a bond if internal.
  • a Ci-6alkyl group for example, contains from one to six carbon atoms in the chain.
  • alkylamino refers to an amino group substituted with at least one alkyl group.
  • alkylthio refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-.
  • amide refers to a group wherein R 9 and R 10 each independently represent a hydrogen or hydrocarbyl group, or R 9 and R 10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
  • amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by
  • R 9 , R 10 , and R 10 ' each independently represent a hydrogen or a hydrocarbyl group, or R 9 and R 10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
  • aminoalkyl refers to an alkyl group substituted with an amino group.
  • aralkyl refers to an alkyl group substituted with an aryl group.
  • aryl as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon.
  • the ring is a 5- to 7-membered ring, more preferably a 6-membered ring.
  • aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
  • Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
  • carboxylate is art-recognized and refers to a group wherein R 9 and R 10 independently represent hydrogen or a hydrocarbyl group.
  • Carbocyclylalkyl refers to an alkyl group substituted with a carbocycle group.
  • carbocycle refers to a non- aromatic saturated or unsaturated ring in which each atom of the ring is carbon.
  • a carbocycle ring contains from 3 to 10 atoms, more preferably from 5 to 7 atoms.
  • Carbocyclylalkyl refers to an alkyl group substituted with a carbocycle group.
  • carbonate is art-recognized and refers to a group -OCO2-.
  • esters refers to a group -C(0)OR 9 wherein R 9 represents a hydrocarbyl group.
  • ether refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O-heterocycle. Ethers include "alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.
  • halo and halogen as used herein means halogen and includes chloro, fluoro, bromo, and iodo.
  • heteroalkyl and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.
  • heteroaryl and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
  • heteroaryl and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
  • Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
  • heteroatom as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.
  • heterocyclylalkyl refers to an alkyl group substituted with a heterocycle group.
  • heterocyclyl refers to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
  • heterocyclyl and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
  • Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
  • Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.
  • hydroxyalkyl refers to an alkyl group substituted with a hydroxy group.
  • lower when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer atoms in the substituent, preferably six or fewer.
  • acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within the aryl group are not counted when counting the carbon atoms in the alkyl substituent).
  • polycyclyl refers to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are "fused rings".
  • Each of the rings of the polycycle can be substituted or unsubstituted.
  • each ring of the polycycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.
  • sulfate is art-recognized and refers to the group -OSC H, or a
  • R 9 and R 10 independently represents hydrogen or hydrocarbyl.
  • sulfoxide is art-recognized and refers to the group-S(O)-.
  • sulfonate is art-recognized and refers to the group SC H, or a
  • substitution refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds.
  • the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
  • the permissible substituents can be one or more and the same or different for appropriate organic compounds.
  • the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
  • Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic mo
  • thioalkyl refers to an alkyl group substituted with a thiol group.
  • thioester refers to a group -C(0)SR 9 or -SC(0)R 9 wherein R 9 represents a hydrocarbyl.
  • thioether is equivalent to an ether, wherein the oxygen is replaced with a sulfur.
  • urea is art-recognized and may be represented by the general formula
  • R 9 and R 10 independently represent hydrogen or a hydrocarbyl.
  • modulate as used herein includes the inhibition or suppression of a function or activity (such as cell proliferation) as well as the enhancement of a function or activity.
  • compositions, excipients, adjuvants, polymers and other materials and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • “Pharmaceutically acceptable salt” or “salt” is used herein to refer to an acid addition salt or a basic addition salt which is suitable for or compatible with the treatment of patients.
  • pharmaceutically acceptable acid addition salt means any nontoxic organic or inorganic salt of any base compounds represented by Formula I.
  • Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
  • Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids. Either the mono or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or
  • the acid addition salts of compounds of Formula I are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.
  • the selection of the appropriate salt will be known to one skilled in the art.
  • Other non-pharmaceutically acceptable salts e.g., oxalates, may be used, for example, in the isolation of compounds of Formula I for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
  • pharmaceutically acceptable basic addition salt means any non-toxic organic or inorganic base addition salt of any acid compounds represented by Formula I or any of their intermediates.
  • Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide.
  • Illustrative organic bases which form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art. Many of the compounds useful in the methods and compositions of this disclosure have at least one stereogenic center in their structure.
  • This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30.
  • the disclosure contemplates all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds, salts, prodrugs or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g., WO 01/062726.
  • Prodrug or “pharmaceutically acceptable prodrug” refers to a compound that is metabolized, for example hydrolyzed or oxidized, in the host after administration to form the compound of the present disclosure (e.g., compounds of formula I).
  • Typical examples of prodrugs include compounds that have biologically labile or cleavable (protecting) groups on a functional moiety of the active compound.
  • Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound.
  • prodrugs using ester or phosphoramidate as biologically labile or cleavable (protecting) groups are disclosed in U.S. Patents 6,875,751, 7,585,851, and 7,964,580, the disclosures of which are incorporated herein by reference.
  • the prodrugs of this disclosure are metabolized to produce a compound of Formula I.
  • the present disclosure includes within its scope, prodrugs of the compounds described herein. Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in "Design of Prodrugs" Ed. H. Bundgaard, Elsevier, 1985.
  • phrases "pharmaceutically acceptable carrier” as used herein means a
  • log of solubility is used in the art to quantify the aqueous solubility of a compound.
  • the aqueous solubility of a compound significantly affects its absorption and distribution characteristics. A low solubility often goes along with a poor absorption.
  • LogS value is a unit stripped logarithm (base 10) of the solubility measured in mol/liter.
  • let-7 activity can be precisely assayed using a luciferase-based method (PSI-Check2 let-7 8X, Fig 1 A).
  • the Renilla luciferase is flanked by 8 repeats of let-7 target sequence and its mRNA will be subject to a higher rate of degradation in the presence of a higher let-7 activity.
  • the control Firefly luciferase was driven by a constitutive promoter (Fig 1A).
  • MCF7, MCF15, Huh7 and Huh7.5.1 were anylyzed to assay the detectable let-7 activity.
  • a cell line with stable integration of the let-7 reporter construct was created.
  • a Neomycin resistance cassette was cloned into the PSI-Check2 let-7- ⁇ ucif erase, and then the reporter plasmid was stably introduced into the Huh7.5.1 cell line and selected with G418 for 3 weeks (Fig IB).
  • the stable cell line was subjected to dual-glo luciferase assay, where it displayed a stable luciferase unit per cell in both Firefly and Renilla (Fig ID).
  • this Huh7.5.1 let-7 luciferase reporter line Huh7.5.1 L7L was transfected with siRNA against LIN28B, as well as let-7 mimics (Fig ID).
  • siRNA effectively reduced LIN28B expression by at least 90%.
  • mature microRNA levels rose about 2 to 3 fold for all let-7 family members.
  • the let-7 activity was reduced by 25-50%, as assayed by dual-glo luciferase.
  • transfection of mimics of let- 7s was used to determine how sensitive the reporter was to changes in let-7 levels (Fig IE and F). This demonstrated that strong induction of let-7 levels by direct transfection was able to effectively silence the reporter (Fig IE).
  • the initial screens with the let-7 reporter stably introduced into Huh cells generated significant numbers of false positives in both directions. As expected, many of the false positive appeared to target luciferase enzymes, and not let-7 activity.
  • replicate wells were transiently transfected with a PSI-Check2 plasmid that either contained the let-7 seed sequence or a clean version that should not be regulated by let-7.
  • the signal change in the screen was then quantified as a function of the effect on the luciferase without let-7 sites, and as a function of internal controls on each reporter consisting of alternate luciferase gene (firefly) driven by a constitutive promoter.
  • AML Acute Myeloid Leukemia
  • Fig 3A-D Focusing on 44, dose curve, time course, and pulse-chase experiments were performed (Fig 3A-D). Varying concentrations of these compounds were applied to Huh7 cells and assayed by RT-PCR for the let-7 sensitive version of HMGA2. These dose curve experiments showed that 44 was effective at luM, and maximally effective at 5uM (Fig 3 A). To determine the time course for activity of 44, cells were treated for various times. RT-PCR for HMGA2 showed that 44 could suppress expression of this let-7 target gene in as few as 8 hours (Fig 3B). Finally, a pulse-chase of treatment was performed with 44 to determine if the effect on let-7 targets was permanent or instigated a feed forward program of suppression of let-7 targets.
  • Phosphodiesterase 10A was identified as a potential target of 44, 61 and 62.
  • the role of phosphodiesterase is to regulate levels of cyclic- AMP (cAMP)(Fig 4). Therefore, if 44 inhibits PDE10, one would expect an increase in cAMP levels leading to CREB activation.
  • Huh cells were treated with 44 and 61 and then stained with an antibody that recognizes phosphorylated CREB, consistent with activation of cAMP signaling. Both 44 and 61 strongly induced levels of nuclear phosopho-CREB (Fig 5A).
  • RNA-seq was carried out to identify which genes are changed in response to treatment with these compounds and whether let-7 targets are enriched amongst these gene expression changes (Fig 5B).
  • Fig 5B A wide variety of genes appeared to be both induced and suppressed.
  • the table below shows a list of genes up- and down regulated by at least 2 fold in response to treatment with 44:
  • Example 4 44 inhibits UPR and PI3K signaling pathways
  • RNAseq was carried out to identify which genes are changed in response to treatment with these compounds and whether let-7 targets are enriched amongst these genes.
  • Example 6 Inhibition of leukemic stem cell proliferation in vivo
  • Ambros V The functions of animal microRNAs. Nature. 2004;431 :350-355.
  • CCAAT/enhancer binding protein alpha up-regulates microRNA let-7a-l in lung cancer cells by direct binding. Cancer Cell Int. 2016;16: 17.
  • Ayyar K Reddy KVR. Transcription factor CCAAT/enhancer-binding protein- beta upregulates microRNA, let-7f-l in human endocervical cells. Am J Reprod Immunol.
  • LIN28B promotes colon cancer progression and metastasis. Cancer research. 2011;71 :4260- 4268.
  • Molenaar JJ Domingo-Fernandez R, Ebus ME, et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature genetics.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés qui sont capables de supprimer les cibles de let-7, d'inhiber la phosphodiestérase, de stimuler cAMP et d'inhiber l'activité de croissance de cellules cancéreuses. L'invention concerne également des méthodes de traitement du cancer.
PCT/US2018/053511 2017-09-29 2018-09-28 Compositions et méthodes de régulation de cibles de micro-arn let-7 Ceased WO2019067955A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566054P 2017-09-29 2017-09-29
US62/566,054 2017-09-29

Publications (1)

Publication Number Publication Date
WO2019067955A1 true WO2019067955A1 (fr) 2019-04-04

Family

ID=65903251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/053511 Ceased WO2019067955A1 (fr) 2017-09-29 2018-09-28 Compositions et méthodes de régulation de cibles de micro-arn let-7

Country Status (1)

Country Link
WO (1) WO2019067955A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207213A1 (fr) * 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Nouveaux inhibiteurs de la signalisation de la protéine kinase c epsilon
US20150140071A1 (en) * 2013-11-12 2015-05-21 Ayyappan K. Rajasekaran Kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207213A1 (fr) * 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Nouveaux inhibiteurs de la signalisation de la protéine kinase c epsilon
US20150140071A1 (en) * 2013-11-12 2015-05-21 Ayyappan K. Rajasekaran Kinase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CINKORNPUMIN, J. ET AL.: "A small molecule screen to identify regulators of let-7 targets", SCIENTIFIC REPORTS, vol. 7, no. 1, 21 November 2017 (2017-11-21), pages 1 - 10, XP055585690, Retrieved from the Internet <URL:https://www. nature .com/articles/s 41598-017 -16258-9> *
DATABASE PubChem BioAssay 21 December 2007 (2007-12-21), "Modulators of the EP 2 prostaglandin E2 receptor - Primary Screening", XP055395475, retrieved from https://pubchem.ncbi.nlm.nih.gov/ bioassay/940 Database accession no. AID 940 *
DATABASE PubChem National Center for Biotechnology Information; 8 July 2010 (2010-07-08), "NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay", XP055585716, Database accession no. 449703 *
LI, Y.: "Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial- to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells", CANCER RESEARCH, vol. 69, no. 16, 15 August 2009 (2009-08-15), pages 6704 - 6712, XP055585705, Retrieved from the Internet <URL:http://cancerres.aacrjoumals.orl content/canres/69 /16/6 704.full.pdf> *
ZIPETO, M. A. ET AL.: "ADAR1 activation drives leukemia stem cell self-renewal by impairing Let-7 biogenesis", CELL STEM CELL, vol. 19, no. 2, 4 August 2016 (2016-08-04), pages 177 - 191, XP029675872, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975616> DOI: doi:10.1016/j.stem.2016.05.004 *

Similar Documents

Publication Publication Date Title
US12162865B2 (en) Methods of treating cancer
McEwan et al. Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle
Mimeault et al. Hypoxia‐inducing factors as master regulators of stemness properties and altered metabolism of cancer‐and metastasis‐initiating cells
US20250304579A1 (en) Compositions and methods for modulating hair growth
Blum et al. Metabolism addiction in pancreatic cancer
JP6509386B2 (ja) ｍＴＯＲ経路関連疾患を治療するための化合物
US20200123127A1 (en) Removal of senescence-associated macrophages
ES2881928T3 (es) Profármacos de etopósido para su uso en el direccionamiento a las células madre cancerosas
US20220048908A1 (en) Compositions and methods for modulating hair growth
KR20210042264A (ko) 요법에서의 사용을 위한 우롤리틴 a 및 그의 유도체
JP2025114717A (ja) 抗腫瘍剤及び配合剤
Lee et al. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
Hou et al. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
ES2958492T3 (es) Glicolípidos y composiciones farmacéuticas de los mismos para uso en terapia
Cruickshanks et al. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy
JPWO2012147901A1 (ja) 抗癌剤副作用改善用組成物
WO2022093809A1 (fr) Amélioration de dégradation de protéines induite par hyt à l&#39;aide de l&#39;administration de nanoparticules lipidiques
WO2019067955A1 (fr) Compositions et méthodes de régulation de cibles de micro-arn let-7
US20230059009A1 (en) Inhibitors of lin28 and methods of use thereof
WO2020242910A1 (fr) Compositions et méthodes de traitement du cancer
Takeuchi et al. Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression
WO2023150793A9 (fr) Inhibiteurs d&#39;enzyme malique 1
US20250082765A1 (en) Molecules as anticancer agents for targeted treatment of breast and prostate cancer
Oikawa et al. Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18863627

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18863627

Country of ref document: EP

Kind code of ref document: A1